Loading treatment…
Prescription onlyOff-label use
Mounjaro®
Prescription — weekly injection pen
The FDA-approved tirzepatide product for type 2 diabetes — the same dual-pathway molecule as Zepbound, prescribed off-label for weight only at a provider's judgment.
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. It is the same molecule as Zepbound, and providers sometimes prescribe it off-label for weight management where they judge it appropriate.
Adding to your plan doesn't order anything and doesn't charge you — it tells the provider what you're hoping to discuss.
About 5 minutes. A licensed provider reviews your health and prescribes mounjaro® only if it's right for you — there is no checkout here, and that's deliberate.
How it works
What it actually does
Mounjaro is tirzepatide — the dual GLP-1/GIP mechanism described on the Zepbound page. Approved for type 2 diabetes; the weight-management indication belongs to Zepbound. Chemically they are the same medication.
See the full mechanism, step by stepA provider may consider it if
- You have type 2 diabetes and weight is part of the picture — its approved use
- Your provider judges the off-label use appropriate for your situation
It won't be prescribed if
- Anyone with a personal or family history of medullary thyroid carcinoma, or MEN 2 syndrome — this is a hard stop
- Pregnancy, trying to become pregnant, or breastfeeding
- A history of pancreatitis, without careful provider review
- Type 1 diabetes, gastroparesis, or an active eating disorder without in-person care
These are the same checks the visit runs. If one applies, the visit will tell you plainly rather than take your money.
What to expect
Realistically, month by month
Weeks 1–4
Starts at 2.5mg weekly — an adaptation dose.
Months 1–6
Steps up as tolerated under provider review, to a maintenance dose that suits you.
Ongoing
Reviewed at check-ins; for diabetes, alongside your existing care.
Safety, stated up front
Side effects, before you decide
As with Zepbound: nausea, diarrhoea, vomiting and constipation, mostly around dose increases; uncommon but serious risks include pancreatitis and gallbladder disease, plus the class boxed warning on thyroid C-cell tumors in rodents.
- FDA prescribing information: Mounjaro (tirzepatide) injection
- Boxed warning: thyroid C-cell tumors in rodents; contraindicated with personal or family history of MTC or MEN 2
Complete safety information is provided during your visit and with every prescription. This page is a summary, not a substitute for your provider's advice.
Questions
Asked honestly, answered honestly
Mounjaro or Zepbound — what's the difference?
The same medication with two labels: Mounjaro is approved for type 2 diabetes, Zepbound for weight management. If weight is the goal, Zepbound is the on-label route; your provider and your coverage decide what makes sense.
See whether mounjaro® is right for you
Five minutes of questions, reviewed by a licensed provider. Treatment only if it's appropriate — and a straight answer either way.